Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.
Am J Transpl. 2012; 12: 388-399
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure.
Am J Transpl. 2009; 9: 2520-2531
Long-term renal allograft survival in the United States: a critical reappraisal.
Am J Transpl. 2011; 11: 450-462
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation.
J Am Soc Nephrol. 2010; 21: 1398-1406
The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.
Am J Transpl. 2018; 18: 293-307
Significance of the positive crossmatch test in kidney transplantation.
N Engl J Med. 1969; 280: 735-739
Antibody-mediated rejection: new approaches in prevention and management.
Am J Transpl. 2018; 18: 3-17
The role of complement in antibody mediated transplant rejection.
Mol Immunol. 2019; 112: 240-246
The importance of C4d in biopsies of kidney transplant recipients.
Clin Dev Immunol. 2013; 2013: 678180
Presentation and outcomes of C4d-negative antibody-mediated rejection after kidney transplantation.
Am J Transpl. 2016; 16: 213-220
Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA).
Am J Transpl. 2011; 11: 56-65
Complement inhibition as potential new therapy for antibody-mediated rejection.
Transpl Int. 2016; 29: 392-402
Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.
Am J Transpl. 2011; 11: 2405-2413
Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year.
Am J Transpl. 2015; 15: 1293-1302
Eculizumab for prevention of antibody-mediated rejection in blood group-incompatible renal transplantation.
Transplant Proc. 2018; 50: 66-69
Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial.
Am J Transpl. 2019; 19: 2876-2888
Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
Am J Transpl. 2019; 19: 2865-2875
Long-term outcomes of eculizumab-treated positive crossmatch recipients: allograft survival, histologic findings, and natural history of the donor-specific antibodies.
Am J Transpl. 2019; 19: 1671-1683
Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment.
J Am Soc Nephrol. 2018; 29: 620-635
The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.
Am J Transpl. 2009; 9: 231-235
Eculizumab and renal transplantation in a patient with CAPS.
N Engl J Med. 2010; 362: 1744-1745
Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation.
Transpl Int. 2011; 24: e61-e66
Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant.
Transpl Proc. 2012; 44: 3033-3036
Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.
Transplantation. 2014; 98: 857-863
Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
Transplantation. 2014; 98: 1056-1059
Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-center experience.
Transpl Proc. 2015; 47: 1754-1759
Eculizumab for the treatment of severe antibody-mediated rejection: A case report and review of the literature.
Case Rep Transplant. 2016; 2016: 9874261
Dosing eculizumab for antibody-mediated rejection in kidney transplantation: a case report.
Transpl Proc. 2016; 48: 3099-3105
Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial.
Am J Transpl. 2017; 17: 682-691
C1 inhibitor, a multi-functional serine protease inhibitor.
Thromb Haemost. 2010; 104: 886-893
A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
Transplantation. 2015; 99: 299-308
C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study.
Am J Transpl. 2016; 16: 1596-1603
Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study.
Am J Transpl. 2016; 16: 3468-3478
A multicenter study to evaluate the efficacy and safety of Cinryze® for the treatment of acute antibody-mediated rejection in participants with kidney transplant (NCT02547220).
(Available at:) (Accessed December 15, 2019)
Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice.
Am J Transpl. 2010; 10: 510-517
Complement-binding anti-HLA antibodies and kidney-allograft survival.
N Engl J Med. 2013; 369: 1215-1226
The perfect storm: HLA antibodies, complement, FcgammaRs, and endothelium in transplant rejection.
Trends Mol Med. 2015; 21: 319-329
IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury.
J Am Soc Nephrol. 2016; 27: 293-304
Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: a systematic review and meta-analysis.
Plos Med. 2018; 15: e1002572
Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: diagnostic misinterpretation has potential therapeutic implications.
Am J Transpl. 2019; 19: 123-131